What is Novavax Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Novavax's interest expense for the
three
months ended in Dec. 2023 was $ -4.1 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.4 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Novavax's Operating Income for the
three
months ended in Dec. 2023 was $ -183.6 Mil. Novavax's Interest Expense for the
three
months ended in Dec. 2023 was $ -4.1 Mil.
Novavax did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Novavax Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax (NAS:NVAX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Novavax's Interest Expense for the
three
months ended in Dec. 2023 was $-4.1 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-183.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $223.9 Mil.
Novavax's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Novavax did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Novavax (Novavax) Business Description
Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
| Filip Dubovsky |
officer: President, R&D |
C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878 |
| Gregory M Glenn |
officer: President, R&D |
20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878 |
| Elaine O'hara |
officer: EVP, Chief Strategy Officer |
333 NORTH WARREN AVENUE, MALVERN PA 19355 |
| John C Jacobs |
director, officer: President and CEO |
630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
| Richard J Rodgers |
director |
C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
| James F Young |
director |
ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Herrmann John A Iii |
officer: SVP, General Counsel |
C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878 |
| Stanley C Erck |
director, officer: President and CEO |
20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878 |
| John Trizzino |
officer: SVP, CBO and CFO |
9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850 |
| David M Mott |
director |
1119 ST. PAUL STREET, BALTIMORE MD 21202 |
| James Patrick Kelly |
officer: EVP, CFO and Treasurer |
C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
| Gary C Evans |
director |
1048 TEXAN TRAIL, GRAPEVINE TX 76051 |
| Rachel K. King |
director |
C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
| Mcmanus Michael A Jr |
director |
241-02 NORTHERN BLVD, DOUGLASTON NY 11362 |
| Margaret G Mcglynn |
director |
C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Novavax (Novavax) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVAX has been successfully added to your 